p53 mutation may be associated with resistance to several chemotherapy agents; but p53 mutant breast cancer may be more sensitive to taxanes, at least in the neoadjuvant setting [5-10], and the predictive value of p53 mutational status in breast cancer remains controversial [3,4]. This evidence concerns the gene TP53 and breast cancer.